TrialDiabetes, obesity & metabolism2020

Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.

Tim Heise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.